Medroxyprogesterone in metastatic renal cell carcinoma

M. K. Rao, Mark S. Soloway

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


We have described a patient in whom complete regression of pulmonary metastases from renal cell carcinoma (RCC) followed treatment with medroxyprogesterone acetate (Depo-Provera). Although the reported rate of objective response to progesterone therapy in RCC is only 10% to 15%, the occasionally dramatic results, especially in men, warrant a trial of this agent. Other more toxic agents have consistently failed to provide significant responses.

Original languageEnglish (US)
Pages (from-to)247-248
Number of pages2
JournalSouthern medical journal
Issue number2
StatePublished - Feb 1980

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Medroxyprogesterone in metastatic renal cell carcinoma'. Together they form a unique fingerprint.

Cite this